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The clinical use of Positron Emission Tomography (PET) imaging using the 2-deoxy-
2-(18F)fluoro-D-glucose (18F-FDG) is currently predominantly focused on diagnostic 
purposes within the field of oncology. Within this context, image analysis is largely 
based on visual interpretation and the use of simple image derived indices, such as 
the maximum standardised uptake value (SUVmax), which corresponds to the voxel 
with the maximum activity concentration within the tumourscaled by the administered 
activity, patient weight andblood glucose concentration.On the other hand, during the 
last few years there has been increasing interest in the use of 18F-FDG PET 
imagingfor the prediction and monitoring of therapy response. Within this context the 
SUVmax has been also predominantly used, where differences between a pre-
treatment and post-treatment scan have been shown to closely correlate with clinical 
response to treatment for a number of different cancer models [1,2]. 
The clear advantage of such a simplistic image derived index is the easiness of 
use which has significantly contributedto its widespread application in clinical 
practice. SUVmaxis also in principle less dependent to partial volume effects (PVE), 
resulting from the limited spatial resolution of PET imaging [3].  On the other hand, 
there are a number of issues associated with its use,such as lack of robustnessin 
terms of image noise, as well as in terms of the reconstruction algorithm and the 
associated corrections used during the reconstruction process.Clearly the impact of 
these issues can be minimised by standardisation of the injection, acquisition,and 
finally image reconstruction and analysis protocols. In addition, the use of peak SUV 
(SUVpeak), measured by averaging the voxel values inside a small region of interest 
centered on the tumor maximum activity concentration voxel, can reduce the SUVmax 
sensitivity to noise, although results may be sensitive to the actual definition of the 
ROI used to compute SUVpeak [4].However and most importantly, SUVmax represents 
only very limitedinformation considering the radiotracer accumulation and no 
information on the associated tumour uptake distribution as well as on the overall 
tumour functional volume. This is true even within the context of static acquisitions 
associated with routine whole body 18F-FDG PET imaging, where one does not 
consider dynamic acquisitions whichoffer the possibility, through kinetic modelling, to 
derive quantitative glucose metabolic rates on a voxel by voxel basis.   
Remaining within the context of static PET imaging, overall tumour activity 
accumulation can be alternatively characterised using the mean standardised uptake 
value (SUVmean). SUVmean corresponds to the mean activity concentration within a 
delineated three dimensional functional tumour volume. The most significant issues 
associated with the accuracy of SUVmeandetermination include the precision and 
robustness in the delineation of the tumour functional volume used [5,6], as well as 
an important influence of PVE which is closely related to the overall tumour size. The 
impact of PVE becomes more significant in the case of response to therapy studies 
where the metabolically active tumour volume (MATV) may change during treatment, 
consequently introducing a variable PVE influence on the calculated difference in 
SUVmean between the baseline and the post-treatment image. All these dependence 
issues combined with the lack of robust tools for tumour volume segmentation and 
PVE correction in PET oncology imaging has previously limited the widespread use 
of SUVmean.    
A combination of the metabolically active tumour volume (MATV) and the 
SUVmean, defined as the total lesion glycolysis (TLG)or total glycolytic volume 
originally proposed by Larson et al [7],would allow in principle a more comprehensive 
functional tumour characterisation. The advantage of such an index is that it includes 
the average level of uptake within the tumour in addition to the spatial extent of the 
tumour uptake distribution, which facilitates the discriminationbetween lesions with 
similar size, but different uptake levels andvice-versa.The potential clinical impact of 
using such a parameter, reflecting overall tumour metabolic information rather than a 
single or few voxel measures based on SUVmaxor SUVpeak respectively, has been 
recently demonstrated. TLG levels derived from a baseline PET image were able to 
predict, in contrast to SUVmax, response to therapy in different cancer models, 
including mesothelioma [8], lymphoma [9] and oesophageal carcinoma[10]. 
However, despite their potential value, image derived indices such as 3D MATV 
and TLG have found only limited useup to date, including within the context of recent 
recommendations for response to therapy assessment using 18F-FDG PET imaging 
[11]. Thiscan be mostly explained by the limited accuracy, robustness and 
reproducibility of the clinically available tumour delineation tools. The shortcomings of 
standard threshold based approaches for MATV, which are currently the only widely 
available in clinical practice, have been previously highlighted in the literature [6,12]. 
They include a strong dependence on overall tumour volume and contrast. On the 
other hand, manual MATV delineation is a time consuming process prone to high 
inter- and intra-operator variability [13]. This renders manual tumor delineation a non-
viable tool for allowing the introduction of MATV as an image derived index in routine 
clinical practice.Different automatic segmentation approaches have been recently 
proposed, motivated by the interest of using 18F-FDG PET for the MATV delineation 
within the field of radiotherapy treatment planning [14]. Some of these approaches 
have shown high robustness and reproducibility to variable quality PET images 
(depending on factors such as scanner sensitivity and image reconstruction 
parameters) and tumour activity distribution characteristics, allowing similar to 
SUVmax physiological reproducibility limits [15]. In addition, the use of these 
approaches has shown promising results for employing MATV measures in the 
prediction and prognosis of response to therapy based on 18F-FDG PET imaging 
[6,10]. However, being able to accurately determine a 3D functional tumour volume 
does not obviate the need for partial volume effects correction in order to ensure the 
calculation of an accurate tumourSUVmean. This extra step clearly further complicates 
the process of accurately determining TLG values. 
For all these reasons a novel parameter entitled SAM or “standardized added 
metabolic” activity parameter, recently proposed by Mertens J and colleagues [16] in 
the European Journal of Nuclear Medicine and Molecular Imaging,may be of 
particular interest. The attractiveness of this parameter is its potential independence 
to an accurate MATV determination as well as partial volume effects. Its derivation is 
based on considering the product of the concentration of activity and corresponding 
volume within two manually defined concentric volumes of interest (VOIs). These 
VOIs are placed around the tumour in sufficient distance from the MATV border to 
avoid partial volume effects. The concentration of activity in the difference VOI is 
used to determine the background activity which is subtracted by the SUVmeanderived 
using the VOI closer to the tumour. Although this parameter contains information 
related to both MATV and SUVmean it does not provide precise 3D tumour volume 
measurements and as such does not require an accurate MATV segmentation 
algorithm or manual tumour delineation. At the same time the mean tumour activity 
concentration calculated within the context of SAM is in principle not influenced by 
partial volume effects. In this same study it was also shown that SAM was less 
influenced by noise compared to the SUVmax.Finally, a potential dependence on the 
scanner calibration and activity injection parameters can beexcluded using 
a“normalized SAM”version by dividing the calculated tumourSAM value with the 
mean background SAM, assuming that the background and the tumour will be 
equally influenced by the different acquisition factors. 
A preliminary clinical evaluation of this new PET image derived parameter was 
performed as part of the same study [16] considering 19 colorectal carcinoma 
patients undergoing baseline and treatment follow-up PET scans (after 3-6 
chemotherapy cycles). In this patient population,consisting of only responders and 
non-responders, no statistically significant differences were found between SUVmaxor 
SAM for assessing response to therapy based on PET imaging. This was the case 
considering either the baseline PET image values or differences between the 
baseline and the follow-up scans. More studies are now necessary considering 
different cancer models and larger and more variable patient populations in order to 
demonstrate the value of SAM not only compared to SUVmax but also in comparison 
to other 18F-FDG PET image derived parameters such as 3D MATV and TLG values 
in terms of both prediction and assessment of response to therapy.   
One can imagine going even further in exploiting tumor activity distribution 
features extracted from static PET images. These include assessing different levels 
of tumour uptake distribution heterogeneity which can eventually correlate with the 
underlying physiological processes governing tumor function. Since some of these 
physiological processes are potential mediators or targets of different therapeutic 
regimes, such image derived indices can be also proposed within the context of 
therapy response prediction and prognosis. Some recent studies have shown the 
interest of such indices for predicting response to therapy in head and neck [17], 
cervical [17] and esophageal cancer [18]. 
Finally it may be appropriate to combine multiple PET image derived indices and 
even multimodality and/or multi-tracer image derived parameters for a more complete 
tumor characterization. Complex correlations will have to be considered given the 
complexity of underlying tumour biology.Molecular profiling of biological specimens 
allows today to reveal the expression level of multiple genes and proteins. Obtaining 
biological specimens requires invasive procedures and may depend on the locationof 
the biopsy within a tumour.Would it be ever possible to imagine as an alternative the 
use of multimodality imaging, combining different image derived indices that will be 
identified as gene expression specific “signatures” and as such allow a non-invasive 
molecular profiling of individual patient cancers? This is still a dream but based on a 
few existing studies we may consider this idea as a future target for becoming reality 
[19]. Only future will tell….. 
In conclusion, we have available today a number of algorithms and approaches 
that allow the automatic or semi-automatic extraction of accurate quantitative 
parameters from the tumor activity distribution in static 18F-FDG PET images. We 
have in this sense reached the age of reason in PET image derived parameters. 
There is now an urgent need for these tools to become widely available in order to 
allow the clinical research community to demonstrate their potential interest for 
therapy assessment, therapy response prediction and patient survival in different 
cancer models. A first step within this process involves standardization, robustness 
and reproducibility studies for all these “novel” PET image derived indices in 
comparison to current “state of the art” in clinical use such as SUVmax. 
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